DK1360208T3 - Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer - Google Patents

Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer

Info

Publication number
DK1360208T3
DK1360208T3 DK00990113T DK00990113T DK1360208T3 DK 1360208 T3 DK1360208 T3 DK 1360208T3 DK 00990113 T DK00990113 T DK 00990113T DK 00990113 T DK00990113 T DK 00990113T DK 1360208 T3 DK1360208 T3 DK 1360208T3
Authority
DK
Denmark
Prior art keywords
antibodies
cancer
patient
tumor
red blood
Prior art date
Application number
DK00990113T
Other languages
English (en)
Inventor
Miyoko Takahashi
David S F Young
Original Assignee
Arius Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arius Res Inc filed Critical Arius Res Inc
Application granted granted Critical
Publication of DK1360208T3 publication Critical patent/DK1360208T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
DK00990113T 2000-11-08 2000-11-08 Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer DK1360208T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2000/002050 WO2003074568A1 (en) 2000-11-08 2000-11-08 Individualized anti-cancer antibodies

Publications (1)

Publication Number Publication Date
DK1360208T3 true DK1360208T3 (da) 2008-08-25

Family

ID=27772923

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00990113T DK1360208T3 (da) 2000-11-08 2000-11-08 Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer

Country Status (11)

Country Link
EP (2) EP1878749A3 (da)
JP (1) JP4826697B2 (da)
AT (1) ATE394425T1 (da)
AU (1) AU2001226985B8 (da)
CA (1) CA2456077A1 (da)
CY (1) CY1108194T1 (da)
DE (1) DE60038824D1 (da)
DK (1) DK1360208T3 (da)
ES (1) ES2306677T3 (da)
PT (1) PT1360208E (da)
WO (1) WO2003074568A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7456258B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
WO1994018345A1 (en) * 1993-02-05 1994-08-18 Affymax Technologies N.V. Receptor-binding antiproliferative peptides
DE69531148T2 (de) * 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern

Also Published As

Publication number Publication date
ES2306677T3 (es) 2008-11-16
AU2001226985B8 (en) 2008-03-13
PT1360208E (pt) 2008-06-11
EP1360208A1 (en) 2003-11-12
CA2456077A1 (en) 2003-09-12
AU2001226985B2 (en) 2008-02-21
JP4826697B2 (ja) 2011-11-30
WO2003074568A9 (en) 2003-12-11
EP1878749A3 (en) 2008-03-19
ATE394425T1 (de) 2008-05-15
EP1878749A2 (en) 2008-01-16
EP1360208B1 (en) 2008-05-07
JP2005519120A (ja) 2005-06-30
CY1108194T1 (el) 2012-05-23
DE60038824D1 (de) 2008-06-19
WO2003074568A1 (en) 2003-09-12
AU2001226985A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
DK1718737T3 (da) Cancerøs sygdomsmodificerende antistoffer
CY1108194T1 (el) Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων
BR112019023409A2 (pt) Métodos para tratar um câncer em um paciente e uma malignidade hematológica, para expandir linfócitos infiltrantes de tumor, linfócitos de sangue periférico e linfócitos infiltrantes de medula, processo para a preparação de uma população de linfócitos infiltrantes de tumor, e, uso de um tumor líquido na fabricação de uma população de linfócitos infiltrantes de tumor.
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
WO2007079293A3 (en) Cancer stem cells and uses thereof
RU2011146654A (ru) Способы лечения рака яичников с применением конъюгированного средства
ATE278408T1 (de) Arsenic hexaoxide (as406) für die verwendung in krebs-therapie und pharmazeutische zubereitungen
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
DK1613656T3 (da) Cancersygdomsmodificerende antistoffer
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2005012361A3 (en) Antibodies raised against colon carcinomas
EP1929034A4 (en) ANTIBODIES CAPABLE OF MODIFYING EVOLUTION OF CANCER DISEASE
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
CN102836430B (zh) 阻断型抗体t5e3在逆转肿瘤多药耐药中的应用
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
Williams The Roy L. Whistler International Award in Carbohydrate Chemistry 2016
EP1757305A3 (en) Individualized anti-cancer antibodies
WO2020076274A2 (en) Development of unique caffeic acid phenethyl ester molecules that are candidates for being cancer drugs and determining biological activities thereof
Antoni Session 1: Rationale for stress management.
WO2008058380A8 (en) Cancerous disease modifying antibodies
Vrecl et al. Effect of capecitabine on mean corpuscular volume of red blood cells